Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
lol
The Virology Department referred to is the Virology department of the Manchester University NHS Foundation Trust. However hope you're right given my holding. With a workload capacity of 300k tests per annum I would agree they will need support.
https://mft.nhs.uk/the-trust/other-departments/laboratory-medicine/manchester-medical-microbiology-partnership/opening-hours-clinical-advice-and-results-line/virology/
My main interest in on the TF test, whether this is being rolled out in UK, and its relation to the Novacyt test as the technological base is very similar however they have referred to their test as being in-house developed by Applied Biosystems. Theirs is the more ambitious target of 5m tests per week and who is involved in their supply chain.
yes, good points there skittish, well done! Regards the shift work mentioned, I thought it was more to do with keeping people apart as opposed to the workload. Might be wrong though!
Just a couple of minor points.
Alderley Park is actually located near Alderley Edge in Cheshire. It is massive. It used to be run by AZ but now by Bruntwood, although AZ still have a major presence.
https://www.alderleypark.co.uk/about-us
Of the 10 PHE sites for laboratory testing that for the North West is located here - Virology Reception, Third Floor, Clinical Science Building 1, Oxford Road, Manchester, M13 9WL.
If you happen to Google Earth that you will see that it is the building which is literally next door to Citylabs 1.0 Nelson Street Manchester M13 9NQ United Kingdom, which actually faces Oxford Road.
https://mspl.co.uk/media/1869/citylabs_brochure_final.pdf
That building houses Yourgene and is also operated by Bruntwood, who as referred to above also operate Alderley Park.
So the address of the PHE lab for North West England is actually in the building next door to Yougene's labs. And we know that Yourgene are doing COVID19 testing for the NHS.
In last weeks webinar Hayden did refer Yourgene having started shift working.
So I suspect that we are in the thick of it.
Thermo 100k tests. I would have assumed it's their own tests and that none of the 3 mega or 10 testing labs are us. We do need more detail and clarification from Yourgene on just what and when we are signed up for.
Short answer is no.
The 3 mega test sites are Milton Keynes, Glasgow and Alderley Park (which is near Sheffield). The commitment to PCR testing is revealed by they being referred to as ‘Lighthouse Labs’ where light is actively used in PCR testing.
The 10 PHE sites for laboratory testing can be found here
https://www.gov.uk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories/wuhan-novel-coronavirus-who-to-call-to-request-laboratory-testing
For Manchester PHE will use Manchester University NHS Foundation Trust. That said it is still a case of waiting for clarification by PHE and the Company. YGEN has existing links with that NHS hospital and it could be, or not, that they will supply the DNA amplification service to them.
Although Novacyt holders have been referring to the Thermo Fisher articles I am confused whether the test that is being referred to is the Novacyt's Primerdesign or Thermo Fisher's Applied Biosystems TaqPath COVID-19 CE-IVD RT-PCR Kit which recently got FDA approval and also was approved for in vitro diagnostic use throughout Europe. Thermo Fisher has said it currently has 1.5 million tests available to ship under the emergency use authorization or EUA label and expects to quickly ramp up to reach 2 million tests per week. The company expects to scale production up to 5 million tests per week during the month of April. The available tests will initially be distributed to about 200 labs in the U.S.
Similar to waiting for clarification on whether an extension to services to Novacyt there also needs to be clarification as to the support that will be provided to Thermo Fisher's COVID-19 testing, both within Europe and in the US.
I also think we need to here a bit more about the part we are now playing and the work we have been doing or are going to be doing in the future.
Yes, I am sure with the agreement in place they will be utilising us to the max. Does anyone know if the Citylabs facility will be used for one of the 3 mega or 10 smaller testing labs?
NCYT CEO Graham Mullis said yesterday "Despite our best efforts to ensure we are fully prepared to meet demand, the rate of sales growth is beginning to be restricted by our ability to scale-up manufacturing as quickly as we would like.
“This, therefore, remains an immediate priority for the company and it is our objective to make as many tests available to as many clinicians around the world as quickly as possible.”
Sounds like we will be asked to ramp it up and expand our production too.Good news I'd say.
So Thermo have agreed to meet the UK demand of 100k tests per day - having read an article in the times they say the tests are carried out at UK testing centres then sent to one of the three big hubs for processing. We really need some clarity over where/if we fit into this side of things - I cannot believe we are not being utilised by Thermo giving our relationship but confirmation and an idea on numbers would be good.
well, in comparison to them they are. Maybe just call them a tiddler then? Hopefully not for much longer though!
Wouldn’t call a company with a £117m mkt cap a micro tiddler
good info, thanks flipper. As a lot of us know YGEN will soon have the best of both worlds with Thermo and Illumina onboard.
not too sure they would bother with micro tiddlers like Ygen.
Well observed Trek.
For those that are unfamiliar with the technology the link below shows the workflow.
https://www.yourgene-health.com/images/iona/c-labs/S5_workflow_image_2.png
Qiagen produce a product called QIAsymphony SP/AS which is used in the IONA workflow to extra DNA which is ultimately sequenced in the TF's ION Chef or ION S5 sequencers. Essentially this acquisition is an example of ThermoFisher buying up the vertical supply chain.
The major suppliers of sequencers are Illumina, ThermoFisher and Roche. The value of the sequencer market is ten-fold that of the NIPT market. However products like NIPT CE-IVD influence which platforms laboratories purchase for their sequencers. Premaitha now YourGene had based their technology on the IONA platform in order to set themselves up as a potential TO target from TF down the track. However this prompted a very painful legal battle with Illumina who could understand the strategic threat this had on their core business. Post their legal settlement YourGene now are on the cusp of delivering an IONA CE-IVD test which works on the Illumina platform. So in some countries YourGene will sell the Illumina version and in some the TF version. They are the only NIPT CE-IVD provider capable (soon) of doing this. Hence the excitement by other posters on this rather than the COVID-19 revenue stream.
In some ways the best analogy is that of a mobile phone app which used to only work on one platform now being able to work on Apple (which if you look into Illumina they're similar to in their strategy). Although YGEN has diversified into other product areas this is essentially the chess game that LTH of NIPT invested into. The main question is with an increasingly diversified product stream, potentially including COVID-19 tests, plus the imminent Illumina IONA test how long does a third-party await.
Well observed Trek.
For those that are unfamiliar with the technology the link below shows the workflow.
https://www.yourgene-health.com/images/iona/c-labs/S5_workflow_image_2.png
Qiagen produce a product called QIAsymphony SP/AS which is used in the IONA workflow to extra DNA which is ultimately sequenced in the TF's ION Chef or ION S5 sequencers. Essentially this acquisition is an example of ThermoFisher buying up the vertical supply chain.
The major suppliers of sequencers are Illumina, ThermoFisher and Roche. The value of the sequencer market is ten-fold that of the NIPT market. However products like NIPT CE-IVD influence which platforms laboratories purchase for their sequencers. Premaitha now YourGene had based their technology on the IONA platform in order to set themselves up as a potential TO target from TF down the track. However this prompted a very painful legal battle with Illumina who could understand the strategic threat this had on their core business. Post their legal settlement YourGene now are on the cusp of delivering an IONA CE-IVD test which works on the Illumina platform. So in some countries YourGene will sell the Illumina version and in some the TF version. They are the only NIPT CE-IVD provider capable (soon) of doing this. Hence the excitement by other posters on this rather than the COVID-19 revenue stream.
In some ways the best analogy is that of a mobile phone app which used to only work on one platform now being able to work on Apple (which if you look into Illumina they're similar to in their strategy). Although YGEN has diversified into other product areas this is essentially the chess game that LTH of NIPT invested into. The main question is with an increasingly diversified product stream, potentially including COVID-19 tests, plus the imminent Illumina IONA test how long does a third-party await.
a bidding war between Thermo and Ilmn would be good
Are you suggesting we may be a target for TF Trek?
Been reading up on TF, they have made accretive acquisitions in the past. They have cash and low leverage, also money is cheap atm. Given the bravado to UK plc about being able to deliver alone the 100k tests I just wonder if they may increase their holding here to get a seat or takeover. There are so many synergies between the two albeit on a different scale both operationally and geographically. Their last acquisition was viewed very favourably by the market. Obviously if they were to move it would be after the finals but they may not wait for the CE approval as that would be a bau transferral. Obviously all just conjecture on my part.
“Qiagen N.V. U.S. shares were up 14%, to $41.24, in early trading.
Thermo Fisher Scientific Inc. said it would acquire Qiagen, a provider of molecular diagnostics and sample preparation technologies, for EUR39 ($43.38). Thermo Fisher shares were up 4%, to $316.35.
The transaction values Netherlands-based Qiagen at about $11.5 billion at current exchange rates, which includes the assumption of about $1.4 billion of net debt, Thermo Fisher said.
Qiagen generated 2019 revenue of $1.53 billion, Thermo Fisher said.”
https://www.marketscreener.com/QIAGEN-N-V-40135659/news/Qiagen-N-Thermo-Fisher-Up-After-Acquisition-Deal-30101982/
Trek